Pfizer Files for IPR of Two Biogen Patents Directed to Rituximab

Goodwin
Contact
LinkedIn
Facebook
X
Send
Embed

In the past few days, Pfizer has filed petitions for IPR of two of Biogen’s patents related to rituximab:  IPR2017-01166 on U.S. Patent 8,329,172 and IPR2017-01167 on U.S. Patent 8,577,244.  According to the petitions, the patents are directed to methods of treating non-Hodgkin’s Lymphoma with rituximab.

The petitions are posted on our IPR Tracker page, along with other selected documents from IPRs of biologic patents.

 

 
Send Print Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide